These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 24633267)

  • 21. A review of the costs of managing childhood epilepsy.
    Beghi E; Frigeni B; Beghi M; De Compadri P; Garattini L
    Pharmacoeconomics; 2005; 23(1):27-45. PubMed ID: 15693726
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A prospective study of direct medical costs in a large cohort of consecutively enrolled patients with refractory epilepsy in Italy.
    Luoni C; Canevini MP; Capovilla G; De Sarro G; Galimberti CA; Gatti G; Guerrini R; La Neve A; Mazzucchelli I; Rosati E; Specchio LM; Striano S; Tinuper P; Perucca E
    Epilepsia; 2015 Jul; 56(7):1162-73. PubMed ID: 26046371
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prevalence and cost of nonadherence with antiepileptic drugs in an adult managed care population.
    Davis KL; Candrilli SD; Edin HM
    Epilepsia; 2008 Mar; 49(3):446-54. PubMed ID: 18031549
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost of epilepsy in Hong Kong: experience from a regional hospital.
    Mak W; Fong JK; Cheung RT; Ho SL
    Seizure; 1999 Dec; 8(8):456-64. PubMed ID: 10627407
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Health care costs decline after successful epilepsy surgery.
    Langfitt JT; Holloway RG; McDermott MP; Messing S; Sarosky K; Berg AT; Spencer SS; Vickrey BG; Sperling MR; Bazil CW; Shinnar S
    Neurology; 2007 Apr; 68(16):1290-8. PubMed ID: 17438219
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of nonadherence to antiepileptic drugs on health care utilization and costs: findings from the RANSOM study.
    Faught RE; Weiner JR; Guérin A; Cunnington MC; Duh MS
    Epilepsia; 2009 Mar; 50(3):501-9. PubMed ID: 19183224
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Economic burden associated with the use of generic antiepileptic drugs in the United States.
    Helmers SL; Paradis PE; Manjunath R; Duh MS; Lafeuille MH; Latrémouille-Viau D; Lefebvre P; Labiner DM
    Epilepsy Behav; 2010 Aug; 18(4):437-44. PubMed ID: 20580619
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Burden of epilepsy: a prevalence-based cost of illness study of direct, indirect and intangible costs for epilepsy.
    Gao L; Xia L; Pan SQ; Xiong T; Li SC
    Epilepsy Res; 2015 Feb; 110():146-56. PubMed ID: 25616467
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Costs of epilepsy and cost-driving factors in children, adolescents, and their caregivers in Germany.
    Riechmann J; Strzelczyk A; Reese JP; Boor R; Stephani U; Langner C; Neubauer BA; Oberman B; Philippi H; Rochel M; Seeger J; Seipelt P; Oertel WH; Dodel R; Rosenow F; Hamer HM;
    Epilepsia; 2015 Sep; 56(9):1388-97. PubMed ID: 26235849
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Analysis of direct, indirect, and intangible costs of epilepsy.
    Pato Pato A; Cebrián Pérez E; Cimas Hernando I; Lorenzo González JR; Rodríguez Constenla I; Gude Sampedro F
    Neurologia; 2011; 26(1):32-8. PubMed ID: 21163205
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The direct medical costs of epilepsy in children and young people: a population-based study of health resource utilisation.
    Ali MA; Elliott RA; Tata LJ
    Epilepsy Res; 2014 Mar; 108(3):576-86. PubMed ID: 24447611
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Management of focal epilepsy in adults treated with polytherapy in France: the direct cost of drug resistance (ESPERA study).
    de Zélicourt M; de Toffol B; Vespignani H; Laurendeau C; Lévy-Bachelot L; Murat C; Fagnani F
    Seizure; 2014 May; 23(5):349-56. PubMed ID: 24560531
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of socio-economic factors causing discontinuation of epilepsy treatment resulting in seizure recurrence: a study in an urban epilepsy clinic in India.
    Das K; Banerjee M; Mondal GP; Devi LG; Singh OP; Mukherjee BB
    Seizure; 2007 Oct; 16(7):601-7. PubMed ID: 17576079
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Economic aspects of drug-resistant epilepsy].
    Owczarek K; Jedrzejczak J
    Neurol Neurochir Pol; 2001; 35(2):309-18. PubMed ID: 11599228
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Economic evaluation of epilepsy in Kiremba (Burundi): a case-control study.
    Nsengiyumva G; Druet-Cabanac M; Nzisabira L; Preux PM; Vergnenègre A
    Epilepsia; 2004 Jun; 45(6):673-7. PubMed ID: 15144433
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comprehensive care of the epilepsy patient--control, comorbidity, and cost.
    Bazil CW
    Epilepsia; 2004; 45 Suppl 6():3-12. PubMed ID: 15315510
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-effectiveness analysis for the use of serum antiepileptic drug level monitoring in children diagnosed with structural-metabolic epilepsy.
    Salih MR; Bahari MB; Shafie AA; Hassali MA; Al-Lela OQ; Abd AY; Ganesan VM
    Epilepsy Res; 2013 Mar; 104(1-2):151-7. PubMed ID: 23103061
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Uptake and costs of care for epilepsy: findings from a U.K. regional study.
    Jacoby A; Buck D; Baker G; McNamee P; Graham-Jones S; Chadwick D
    Epilepsia; 1998 Jul; 39(7):776-86. PubMed ID: 9670907
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The economic burden of epilepsy in Bhutan.
    Wibecan L; Fink G; Tshering L; Bruno V; Patenaude B; Nirola DK; Dorji C; Dema U; Pokhrel D; Mateen FJ;
    Trop Med Int Health; 2018 Apr; 23(4):342-358. PubMed ID: 29369457
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Household costs of mental health care in Ghana.
    Addo R; Nonvignon J; Aikins M
    J Ment Health Policy Econ; 2013 Dec; 16(4):151-9. PubMed ID: 24526584
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.